Bone Biologics (BBLG) Receivables - Other (2014 - 2015)
Bone Biologics (BBLG) posted quarterly Receivables - Other of $75000.0 for Q3 2015, down 50.0% quarter-over-quarter from $150000.0 in Q2 2015.
Powered by 
Analysis
Bone Biologics (BBLG) Receivables - Other (2014 - 2015) Analysis & Trends
Bone Biologics (BBLG) has reported Receivables - Other for 2 consecutive years, with $75000.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Receivables - Other changed N/A year-over-year to $75000.0; the TTM figure through Sep 2015 stood at $75000.0 (changed N/A YoY), while the FY2015 annual figure was -$75000.0, down 200.0% from the prior year.
- Receivables - Other retreated to $75000.0 in Q3 2015 per BBLG's latest filing, from $150000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $150000.0 in Q2 2015 and bottomed at $75000.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | 75,000.00 |
| Jun 30, 2015 | 150,000.00 |
| Dec 31, 2014 | 75,000.00 |